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LETTER TO THE EDITOR - REPLY 
We thank Drs Van Kruiningen and Tonelli for their letter underlying the role of obstructed 
lymphatics in the pathogenesis of Crohn’s disease (CD). Indeed, the forgotten role of lym-
phangitis in CD has been revisited.1 Of note, it was consistently reported that at an early time, a 
fundamental alteration in CD occurs in the regional lymphatics of the intestine, highlighting the 
role of lymphatics in the genesis of disease.2 Rahier et al3 have confirmed that the lymphatic 
vessels’ density was increased in CD patients compared with controls, with a progressive 
increase in lymphatic density seen from non-inflamed to inflamed areas and the phenomenon 
present in areas with no other marker of inflammation, suggesting an early event. However, a 
causal role for these alterations has not been consistently demonstrated in CD; the vast majority 
of predisposing genes highlighted in CD do not point toward a prominent role of lymphatics as a 
cause of the disease, and finally, marked and clinically significant fibrosis only occurs in a subset 
of CD patients and is associated to a specific immune-inflammatory process not necessarily 
associated with lymphatic abnormalities. This is why we did not address the impact of 
obstructed lymphatics in fibrosis and penetrating complications. 
Moreover, our article mostly aimed at better describing the pathophysiology of intestinal 
damage lesions in CD to further allow the identification of new therapeutic targets to prevent 
and reverse tissue damage and especially fibrosis. We reported the direct antifibrotic action of 
several existing or newly developed molecules and cell therapies targeting transforming growth 
factor beta1 induced pathways, extracellular matrix deposition, and epithelial-to-mesenchymal 
transition. On the opposite, no clear target has emerged so far to prevent or correct lymphatic 
lesions described in CD, and there is no proof that it would impact transmural lesions and 
fibrosis development. Although research in this field is important and may help to better 
understand the pathogenesis of CD, over the short-term, we do not see it as a major way to find 
new treatments to treat transmural tissue damage and fibrosis in inflammatory bowel disease. 
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